計(jì)小清,趙鳳榮,辛麗娟Δ,計(jì)國旗,王月,尹金鵬
(1.承德醫(yī)學(xué)院 中醫(yī)系,河北 承德 067000;2.承德縣醫(yī)院 重癥監(jiān)護(hù)室,河北 承德 067400)
四君子湯合當(dāng)歸補(bǔ)血湯對(duì)荷瘤小鼠化療后免疫功能的影響
計(jì)小清1,趙鳳榮2,辛麗娟1Δ,計(jì)國旗1,王月1,尹金鵬1
(1.承德醫(yī)學(xué)院 中醫(yī)系,河北 承德 067000;2.承德縣醫(yī)院 重癥監(jiān)護(hù)室,河北 承德 067400)
目的觀察四君子湯合當(dāng)歸補(bǔ)血湯對(duì)環(huán)磷酰胺化療荷瘤小鼠的免疫保護(hù)作用。方法建立小鼠肉瘤S180移植性腫瘤模型,24 h后隨機(jī)分為5組:荷瘤對(duì)照組、環(huán)磷酰胺組(cyclophosphamide,CTX)、四君子湯合當(dāng)歸補(bǔ)血湯大中小3個(gè)劑量組。荷瘤對(duì)照組給予生理鹽水腹腔注射0.2mL/(只·d),生理鹽水灌胃0.4mL/(只·d);環(huán)磷酰胺組給予腹腔注射CTX 20mg/(kg·d),生理鹽水灌胃0.4mL/(只·d);四君子湯合當(dāng)歸補(bǔ)血湯小劑量組給予CTX腹腔注射20mg/(kg·d),中藥灌胃0.1 g/(只·d);四君子湯合當(dāng)歸補(bǔ)血湯中劑量組給予CTX腹腔注射20mg/(kg·d),中藥灌胃0.2 g/(只·d);四君子湯合當(dāng)歸補(bǔ)血湯大劑量組給予CTX腹腔注射20mg/(kg·d),中藥灌胃0.4 g/(只·d)。每日用藥1次,10 d后,計(jì)算脾臟及胸腺指數(shù),測定NK細(xì)胞活性,檢測T淋巴細(xì)胞增殖能力。結(jié)果四君子湯合當(dāng)歸補(bǔ)血湯3個(gè)劑量組均能在一定程度上提高化療荷瘤小鼠的脾臟胸腺指數(shù)、NK細(xì)胞活性及T淋巴細(xì)胞增殖能力,尤其是中劑量組和大劑量組效果明顯,與單純化療組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05,P<0.01)。結(jié)論四君子湯合當(dāng)歸補(bǔ)血湯能拮抗化療引起的小鼠機(jī)體免疫功能下降。
四君子湯;當(dāng)歸補(bǔ)血湯;化療;免疫功能
1.1 材料
1.1.1 實(shí)驗(yàn)動(dòng)物及細(xì)胞株 清潔級(jí)昆明小鼠,50只,雌雄各半,體質(zhì)量(20±2)g,購自北京維通利華實(shí)驗(yàn)動(dòng)物有限公司,許可證:SCXK(京)2006-0000。腹腔接種小鼠肉瘤S180細(xì)胞后4天的昆明種小鼠,8只,雌雄各半,體質(zhì)量25~26 g,由北京維通利華實(shí)驗(yàn)動(dòng)物有限公司提供,許可證:SCXK(京)2006-0000。K562細(xì)胞株由承德醫(yī)學(xué)院附屬醫(yī)院中心實(shí)驗(yàn)室提供。
1.1.2 藥品 四君子湯(人參、白術(shù)、茯苓、甘草)、當(dāng)歸補(bǔ)血湯(黃芪、當(dāng)歸)(飲片均購自北京同仁堂),劑量配比以第七版全國高等中醫(yī)藥院校教材《方劑學(xué)》為準(zhǔn),將所有的中藥均用水浸泡大約 20 min,煎煮、過濾 3次,每次持續(xù) 30 min,取約300m L汁液,通過80℃水浴濃縮,標(biāo)準(zhǔn)為每毫升含生藥1 g,將藥液置于4℃冰箱內(nèi)保存,備用?;熕幬镒⑸溆铆h(huán)磷酰胺(山西普德藥業(yè)股份有限公司,批號(hào):04110601)。
1.1.3 試劑及儀器 二甲基亞砜(DMSO,天津市天大化工實(shí)驗(yàn)廠),四氮甲唑藍(lán)(MTT,Sigma公司),刀豆蛋白 A(ConA,Sigma公司),RPMI-1640(GIBCO,invitrogen),MCO-15AC CO2恒溫培養(yǎng)箱(SANYO,日本),680酶標(biāo)儀(BIO-RAD,美國),SHJ系列潔凈工作臺(tái)(中國上海上凈凈化設(shè)備公司)。
1.2 實(shí)驗(yàn)方法
1.2.1 動(dòng)物模型的建立 將腹腔接種小鼠肉瘤S180細(xì)胞后7天的昆明種小鼠頸椎脫臼處死,腹部皮膚消毒后抽取腹水(乳白色濃稠液)按1∶6比例生理鹽水稀釋,調(diào)整細(xì)胞濃度為2×107個(gè)/mL,75%酒精消毒接種于小鼠的右腋皮下,每只0.2mL,各組小鼠接種位置及深度一致。
1.2.2 實(shí)驗(yàn)分組及給藥 清潔級(jí)昆明種小鼠隨機(jī)分為5組,每組10只。分組如下:①荷瘤對(duì)照組:生理鹽水腹腔注射0.2mL/(只·d);生理鹽水灌胃 0.4mL/(只·d);②環(huán)磷酰胺組(cyclophosphamide,CTX):腹腔注射 CTX 20mg/(kg·d);生理鹽水灌胃0.4mL/(只·d);③四君子湯合當(dāng)歸補(bǔ)血湯小劑量組:CTX腹腔注射20mg/(kg·d);中藥灌胃0.1 g/(只·d);④四君子湯合當(dāng)歸補(bǔ)血湯中劑量組:CTX腹腔注射20mg/(kg·d);中藥灌胃0.2 g/(只·d);⑤四君子湯合當(dāng)歸補(bǔ)血湯大劑量組:CTX腹腔注射20mg/(kg·d);中藥灌胃0.4 g/(只·d)。
2種湯藥混在一起灌胃,按七版方劑學(xué)規(guī)定的四君子湯及當(dāng)歸補(bǔ)血湯常規(guī)劑量為中劑量,常規(guī)劑量的1/2為小劑量,常規(guī)劑量的2倍為大劑量;小中大3個(gè)劑量組的濃度分別是每0.4 mL含中藥0.1 g、0.2 g及0.4 g。各組小鼠的灌胃容積采取的標(biāo)準(zhǔn)為0.4mL/只,腹腔注射的標(biāo)準(zhǔn)均為0.2mL/只。各組小鼠的用藥時(shí)間為瘤細(xì)胞接種24 h后,每天1次,連續(xù)10 d,末次給藥后24 h處死動(dòng)物。
1.3 檢測指標(biāo)
1.3.1 脾臟及胸腺指數(shù) 小鼠頸椎脫臼處死,稱體重,摘取脾及胸腺稱重,脾或胸腺指數(shù)為脾或胸腺重量(mg)與體質(zhì)量(g)之比。
1.3.2 MTT法測定NK細(xì)胞的活性 在無菌條件下,采用酶消化法制備動(dòng)物模型的脾細(xì)胞懸液,用鑷子將脾臟夾碎,加入400 U/mL的膠原酶(III型),每只脾臟 5 mL,于 37℃消化20min,尼龍網(wǎng)過濾,獲得單細(xì)胞懸液。孵箱內(nèi)培養(yǎng),條件為:37℃、5%CO2、120min,去除粘附細(xì)胞,用培養(yǎng)液分別將培養(yǎng)細(xì)胞數(shù)和傳代良好的K562細(xì)胞稀釋至2×106個(gè)/mL和1×105個(gè)/ml。在96孔板中觀察組的孔依次加入K562細(xì)胞和效應(yīng)細(xì)
胞各90 ul,對(duì)照組的孔內(nèi)只加入180μL效應(yīng)細(xì)胞或靶細(xì)胞(K562細(xì)胞),將總體積調(diào)至200μL左右,在所有的孔內(nèi)均加入10μL濃度為5mg/mL的MTT,于孵箱內(nèi)培養(yǎng)4 h,離心,棄上清。加入150μLDMSO,振蕩5min,酶標(biāo)儀測定OD570值。NK細(xì)胞活性計(jì)算方法如下:
1.3.3 T淋巴細(xì)胞增殖能力的測定[7]在無菌條件下,摘取動(dòng)物模型的脾臟,制備脾細(xì)胞懸液,用RPMI-1640培養(yǎng)基調(diào)細(xì)胞懸液濃度至5×106/L,在96孔內(nèi)分別加入細(xì)胞培養(yǎng)液和ConA,各100μL/孔,調(diào)整終濃度至 6 ug/m L,將上述加好的培養(yǎng)板置培養(yǎng)箱68 h后取出,每孔吸出10μL后,再加入10μL濃度為0.5 g/L MTT,置培養(yǎng)箱內(nèi)再培養(yǎng)4 h取出,在每孔內(nèi)加100μL濃度為10%SDS-HCl溶液,振蕩過夜,采用酶標(biāo)儀測定各孔內(nèi)OD57nm值。用A值來表示T淋巴細(xì)胞增殖能力。
1.4 統(tǒng)計(jì)學(xué)方法 采用SPSS17.0統(tǒng)計(jì)學(xué)軟件,各組數(shù)據(jù)以“±s”表示,對(duì)結(jié)果進(jìn)行單因素方差分析,以P<0.05為差異有統(tǒng)計(jì)學(xué)意義。
2.1 對(duì)化療荷瘤小鼠臟器指數(shù)的影響 由表1可見,環(huán)磷酰胺化療組小鼠胸腺指數(shù)、脾臟指數(shù)明顯下降,與荷瘤對(duì)照組比較差異均有統(tǒng)計(jì)學(xué)意義(P<0.01);與環(huán)磷酰胺化療組比較,四君子湯合當(dāng)歸補(bǔ)血湯各劑量組胸腺指數(shù)及脾臟指數(shù)均有一定程度的升高,尤其是中劑量組和大劑量組升高明顯,差異有統(tǒng)計(jì)學(xué)意義(P<0.05,P<0.01)。
表1 二方合用對(duì)化療荷瘤小鼠臟器指數(shù)的影響(g/kg)Tab.1 The effect of two decoction on viscera index on chemotherapy tumor bearingmice(g/kg)
2.2 對(duì)化療荷瘤小鼠NK細(xì)胞活性和T淋巴細(xì)胞增殖能力的影響 由表2可見,環(huán)磷酰胺化療組小鼠NK細(xì)胞活性明顯下降,與荷瘤對(duì)照組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.01);與環(huán)磷酰胺化療組比較,四君子湯合當(dāng)歸補(bǔ)血湯各劑量組NK細(xì)胞活性均有提高,尤其是中劑量組和大劑量組升高明顯,差異有統(tǒng)計(jì)學(xué)意義(P<0.01)。環(huán)磷酰胺化療組小鼠T淋巴細(xì)胞增殖程度明顯降低,與荷瘤對(duì)照組比較差異顯著(P<0.01);與環(huán)磷酰胺化療組比較,四君子湯合當(dāng)歸補(bǔ)血湯各劑量組均可促進(jìn)T淋巴細(xì)胞增殖,尤其是中劑量組和大劑量組提升明顯,差異有統(tǒng)計(jì)學(xué)意義,分別是(P<0.05,P<0.01)。
表2 二方合用對(duì)化療荷瘤小鼠NK細(xì)胞活性及T淋巴細(xì)胞增殖能力的影響Tab.2 The effect two decoction on NK cells activity and T lymphocyte proliferation in tumor bearingmice
在當(dāng)今惡性腫瘤的治療中,化療是其主要手段之一。但化療在發(fā)揮殺傷腫瘤細(xì)胞作用的同時(shí),不可避免會(huì)發(fā)生不良反應(yīng),抑制人體的免疫機(jī)能,從而引起免疫功能下降。針對(duì)這種情況,在化療的同時(shí)配合中醫(yī)的扶正固本法以增加人體免疫力,成為現(xiàn)今中西醫(yī)結(jié)合治療惡性腫瘤的研究熱點(diǎn)之一[8-12]。四君子湯是健脾益氣的經(jīng)典方,當(dāng)歸補(bǔ)血湯是補(bǔ)氣生血的有效方,相關(guān)研究證實(shí),二方單用均能在一定程度上拮抗化療引起的機(jī)體免疫功能下降[13-14],但二方各有側(cè)重,所以本實(shí)驗(yàn)將二方合用,分成3個(gè)劑量組,探討二方合用對(duì)荷瘤小鼠化療后免疫功能下降的抵抗效果。
脾臟和胸腺的重量及免疫器官指數(shù)是反映動(dòng)物免疫器官發(fā)育狀況好壞的最基本的指標(biāo),免疫功能低下小鼠的脾臟指數(shù)和胸腺指數(shù)明顯低于正常小鼠[15]。本次實(shí)驗(yàn)結(jié)果提示四君子湯合當(dāng)歸補(bǔ)血湯聯(lián)合化療較單純化療能提高荷瘤小鼠整體的免疫功能狀態(tài)。NK細(xì)胞是機(jī)體內(nèi)一種重要的免疫細(xì)胞,在機(jī)體的免疫監(jiān)視,抗腫瘤,抗感染過程中起著積極的作用[3]。另外,作為體內(nèi)的重要的免疫細(xì)胞的T淋巴細(xì)胞在抗腫瘤和免疫調(diào)等方面發(fā)揮著很重要的作用。其中,T淋巴細(xì)胞在ConA等的誘導(dǎo)下會(huì)發(fā)生增殖。因此,在臨床或者檢測方面常把T淋巴細(xì)胞的增殖效果作為評(píng)價(jià)T細(xì)胞功能的一個(gè)指標(biāo),反映機(jī)體免疫狀況[7]。本次實(shí)驗(yàn)結(jié)果顯示,荷瘤小鼠經(jīng)過10天的化療后,NK細(xì)胞活性及T淋巴細(xì)胞增殖能力均顯著下降,表明化療造成小鼠免疫功能受損。而在化療的同時(shí)給予小鼠灌胃四君子湯合當(dāng)歸補(bǔ)血湯,兩項(xiàng)指標(biāo)均有不同程度的提升,尤其中劑量組和大劑量組的中藥效果更為明顯。說明四君子湯與當(dāng)歸補(bǔ)血湯合用后能更好的發(fā)揮扶正固本作用,有效抵抗化療對(duì)細(xì)胞免疫功能的影響。
綜上所述,二方合用對(duì)由化療引起的免疫器官受損具有明顯的保護(hù)效果,有效抑制化療引起的細(xì)胞免疫功能下降等不良反應(yīng),但其調(diào)節(jié)免疫作用的機(jī)制有待進(jìn)一步探討。
[1]《方劑學(xué)》.人民衛(wèi)生出版社(第1版),2002:182-185,199-200.
[2]WANG L,LUO X,PAN H,et al.Protective Effectof Polysaccharides of Sijunzi Decoction on Intestinal Mucosa and Systematic Immune in Tumor-bearing Mice After Chemotherapy[J].Journal of Guangzhou University of Traditional Chinese Medicine,2012,29(6):17-19.
[3]Han CY,Liu CY,Shi JB,et al.The antioxidant activity of fermented decoction of Sijunzi in S 180-bearing mice[J].Chinese Journal of Microecology,2010,2(7):591-593.
[4]尤紅煜,連偉光,張煥鈴,等.順鉑聯(lián)合樹突狀細(xì)胞疫苗對(duì)荷瘤小鼠的抗腫瘤作用[J].中華腫瘤雜志,2012,34(5):336-340.
[5]LIU J,CHU J.Pharmacodynamics Study of Danggui Buxue Decoction Extracted by Different Methods in Anemia Model Mice Induced by Chemotherapy[J].Journal of Liaoning University of Traditional Chinese Medicine,2011,28(8):52-54.
[6]顧群浩,張曉東,蔡照弟,等.大腸癌術(shù)后患者四君子湯應(yīng)用觀察[J].山東醫(yī)藥,2012,52(34):73-74.
[7]Li X T,Wang B,Li JL,etal.Effectsof Dangguibuxue Tang,a Chinese herbal medicine,on growth performance and immune responses in broiler chicks[J].Biological research,2013,46(2):183-188.
[8]蔣立峰,劉懷民.當(dāng)歸補(bǔ)血湯防治腫瘤化療后骨髓抑制臨床觀察[J].中醫(yī)學(xué)報(bào),2013,28(4):475-477.
[9]XIE B,HUANG X,LIU M,et al.Effects of Modified Danguibuxuetang Concentrated Pills on S_(180)Tumor Model in BALB/c-nu/nu Treated with CTX[J].Lishizhen Medicine and Materia Medica Research,2010,12(7):124-126.
[10]LI Y,LI J.Experimental study of Paclitaxel and Sijunzi Decoction therapeutics in NPC model[J].Chinese Journal of Biochemical Pharmaceutics,2011,15(3):115-117.
[11]Lin Y L,Lai W L,Harn H,et al.The Methanol Extract of Angelica sinensis Induces Cell Apoptosis and Suppresses Tumor Growth in Human Malignant Brain Tumors[J].Evidence-Based Complementary and Alternative Medicine,2013,13(8):9-10.
[12]孫運(yùn)良,徐燦,蘇長青,等.重組腺病毒介導(dǎo)Hsp70基因表達(dá)對(duì)胰腺癌荷瘤小鼠的免疫功能影響[J].重慶醫(yī)學(xué),2012,41(32):3353-3355,3359.
[13]Gao J,Huang Y,Li P,et al.Antifibrosis effects of total glucosides of Danggui-Buxue-Tang in a rat model of bleomycin-induced pulmonary fibrosis[J].Journal of ethnopharmacology,2011,136(1):21-26.
[14]WANG X,WANG T,WANG Y,et al.Effect of Serum Containing Drug of Danggui Buxue Decoction on the Proliferation of Mice Bone Marrow Stromal Cells and Expression of Cytokines[J].Liaoning Journal of Traditional Chinese Medicine,2011,7(2):5-8,16.
[15]楊艷梅,熊德上,徐酉華,等.寧血飲對(duì)ITP模型小鼠血小板系統(tǒng)和免疫功能的影響[J].重慶醫(yī)學(xué),2011,40(22):2199-2201,2205.
(編校:吳茜)
Effects of Sijunzi decoction and Danggui Buxue decoction on immunologic function in tumor-bearing m ice treated by chemotherapy
JIXiao-qing1,ZHAO Feng-rong2,XIN Li-juan1Δ,JIGuo-qi1,WANG Yue1,YIN Jin-peng1
(1.College of TCM,ChengDe Medical College,Chende 067000,China;
2.Intensive Care Unit,Hospital of Cheng De county,Chende 067000,China)
ObjectiveTo explore the protective effect of Sijunzi decoction and Danggui Buxue decoction on the immunological function in tumorbearingmice treated by cyclophosphamide.MethodsTransplantable carcinomas animalmodelwere constructed by inoculating tumor cell tomice for 24 hours,and random ly divided into five groups.Tumor-bearing control group were reveived normal saline 0.2 mL per mice one day by intraperitoneal injection,and normal saline 0.4mL permice each day by intragastric administration.Cyclophosphamide group were reveived CTX 20mg per kgweight each day,and normal saline 0.4mL permice each day.Sijunzidecoction and Danggui Buxue Decoction low dose group were reveived CTX 20mg per kg weight each day and traditional Chinese medicine 0.1 g per mice each day.Sijunzi decoction and Danggui Buxue Decoction mediate dose group were reveived CTX 20mg per kg weight each day and traditional Chinesemedicine 0.2 g permice each day.Sijunzi decoction and Danggui Buxue Decoction high dose group were reveived CTX 20 mg per kg weight each day and traditional Chinese medicine 0.4 g per mice each day.The weight indices of thymus gland and spleen,NK-cell activity and the proliferation of T-lymphocyte in five groupsweremeasured after ten 10 days treatment.ResultsThe weight indices of thymus gland and spleen,NK-cell activity and the proliferation of T-lymphocyte were increased in all three Sijunzi decoction and Danggui Buxue decoction groups,especially in Sijunzi decoction and Danggui Buxue decoction mediate and high dose group,the differences between them and CTX group were statistically significan(P<0.05,P<0.01).ConclusionSijunzi decoction and Danggui Buxue decoction can antagonize the decrease of immunological function in tumor-bearingmice treated by chemotherapy.
Sijunzi decoction;Danggui Buxue decoction;chemotherapy;immunological function
R273
A
1005-1678(2014)03-0021-03
四君子湯是健脾益氣、扶正祛邪的經(jīng)典方,當(dāng)歸補(bǔ)血湯是金元四大家之一李東垣創(chuàng)造的益氣補(bǔ)血著名方劑[1]。相關(guān)研究表明[2-6],四君子湯及當(dāng)歸補(bǔ)血湯單用均能抵抗化療引起的機(jī)體免疫功能下降,但當(dāng)歸補(bǔ)血湯偏于補(bǔ)氣生血,而四君子湯偏于補(bǔ)氣健脾。本研究通過建立S180荷瘤小鼠模型,探討二方合用對(duì)荷瘤小鼠化療后免疫功能下降的抵抗效果,為臨床評(píng)估二方合用的療效提供有效的科學(xué)依據(jù)。
河北省高等學(xué)??茖W(xué)技術(shù)研究青年基金項(xiàng)目(2010105)
計(jì)小清,女,碩士,講師,研究方向:中醫(yī)方劑配伍規(guī)律,E-mail:401315971@qq.com;辛麗娟,通信作者,女,本科,實(shí)驗(yàn)師,研究方向:實(shí)驗(yàn)動(dòng)物學(xué),E-mail:401315971@qq.com。